University Hospitals Cleveland Medical Center

Escalating Doses of Memantine in Down Syndrome (MEDS-123)

Phase 1Not yet recruiting202625 people15 Apr 2026clinicaltrials.gov

NCT05457972

Phase 4Recruiting2025100 people14 Jul 2022clinicaltrials.gov

NCT05085834

Early phase 1Completed202095 people20 Oct 2021clinicaltrials.gov

Impact of Mesenchymal Stem Cells in Knee Osteoarthritis

Phase 1Completed201816 people27 Mar 2018clinicaltrials.gov

NCT02872597

Phase 1Completed201630 people19 Aug 2016clinicaltrials.gov

NCT02866721

Phase 1Completed201614 people15 Aug 2016clinicaltrials.gov

NCT02807441

Phase 3Withdrawn20160 people21 Jun 2016clinicaltrials.gov

NCT02433587

Phase 3Withdrawn20190 people5 May 2015clinicaltrials.gov

NCT02304302

Phase 2Completed2014160 people1 Dec 2014clinicaltrials.gov

NCT01717040

Phase 4Terminated201237 people30 Oct 2012clinicaltrials.gov

NCT01526148

Phase 4Terminated201242 people3 Feb 2012clinicaltrials.gov

NCT01093417

Phase 2Completed201045 people25 Mar 2010clinicaltrials.gov

NCT00835120

Phase 4Completed200934 people3 Feb 2009clinicaltrials.gov

NCT00597415

Phase 2Status unknown200430 people18 Jan 2008clinicaltrials.gov

NCT00221975

Phase 3Completed200298 people22 Sept 2005clinicaltrials.gov

NCT00194064

Phase 3Terminated200218 people19 Sept 2005clinicaltrials.gov

NCT00194129

Phase 3Completed199731 people19 Sept 2005clinicaltrials.gov

NCT00194090

Phase 4Completed200440 people19 Sept 2005clinicaltrials.gov

NCT00063362

Phase 3Terminated200249 people27 Jun 2003clinicaltrials.gov